PALO ALTO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 6, 2021, the compensation committee of BridgeBio’s board of directors granted nine new employees restricted stock units for an aggregate of 12,073 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).